Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Cellectis S.A.

Cellectis S.A. (CLLS) Stock Overview

Explore Cellectis S.A.’s financial performance, market position, analyst ratings, and future outlook.

CLLS●NASDAQ
HealthcareBiotechnology
$1.53
$0.07(4.79%)
U.S. Market opens in 10h 15m

Cellectis S.A. (CLLS)

Meyka AI Score

Z

Key Financials

Market Cap153.6M
P/E Ratio-2.30
EPS (TTM)$-0.67
ROE-0.94%
Fundamental Analysis

AI Price Forecasts

1 Month$1.97
3 Months$2.85
1 Year Target$4.86

CLLS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Cellectis S.A. (NASDAQ: CLLS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Cellectis S.A.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of CLLS on the NASDAQ shows an RSI of 22.76, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $4.86 for the NASDAQ listing.

Key metrics behind Cellectis S.A.'s NASDAQ-traded stock include a P/E ratio of -2.30 and a market capitalization of 153.6M. Combined with our AI analysis, these give both institutional and retail investors a clear view of CLLS on the NASDAQ.

Price Performance (NASDAQ: CLLS)

1-Day Change
4.79%
5-Day Change
-50.80%
1-Month Change
-49.67%
3-Month Change
-48.66%
6-Month Change
-55.91%
Year-to-Date (YTD) Change
-68.39%
1-Year Change
-51.58%
3-Year Change
-6.13%
5-Year Change
-88.67%
All-Time (Max) Change
-96.31%

Contact Information

https://www.cellectis.com
33 1 81 69 16 00
8, rue de la Croix Jarry, Paris, IF, 75013

Company Facts

2,290 Employees
IPO DateMar 24, 2015
CountryFR
Actively Trading

Frequently Asked Questions